SENSEX NIFTY
You are here : Moneycontrol > Mutual Funds > Sector - Pharma & Healthcare > Reliance Mutual Fund > Reliance Pharma Fund (G)

Reliance Pharma Fund (G) SET SMS ALERT

101.283
2.19 (2.21%)
NAV as on Jul-30-2014
ranking by CRISIL

Not Ranked

This scheme is not ranked by CRISIL (for quarter ended Mar 2014) since it does not fulfill certain eligibility criteria of CRISIL

View Top ranked funds in other categories

Benchmark Index:
 
View Historic Graph From     To     

Returns (NAV as on Jul-30-2014)

Period Returns (%) Rank #
1 mth 4.2 6
3 mth 11.8 6
6 mth 20.2 6
1 year 44.2 4
2 year 29.1 2
3 year 19.6 2
5 year 28.8 1

# Moneycontrol Rank within 6 Sector - Pharma & Healthcare Schemes.

Absolute Returns (in %)

Year Qtr 1 Qtr 2 Qtr 3 Qtr 4 Annual
2014 3.5 10.8 - - -
2013 -6.3 5.4 3.2 14.6 20.5
2012 8.6 4.0 10.7 5.7 34.9
2011 -8.0 7.5 -7.5 -4.2 -11.6
2010 11.0 8.7 0.9 6.6 32.0
2009 -5.4 33.0 40.9 -0.2 116.7

View where it stands within its peers

* Returns over 1 year are Annualised

Performance

Fund returns v/s Category average (Sector - Pharma & Healthcare)

* Returns over 1 year are Annualised
  1 mth (%) 3 mth (%) 6 mth (%) 1 yr (%) 2 yr (%) 3 yr (%) 5yr (%)
Fund Returns 4.2 11.8 20.2 44.2 29.1 19.6 28.8
Category avg 6.6 14.4 22.4 42.9 15.6 11.1 13.8
Difference of Fund returns and Category returns -2.4 -2.6 -2.2 1.3 13.5 8.5 15.0
Best of category 8.0 17.2 25.8 46.9 36.0 27.3 28.8
Worst of category 4.2 11.8 20.2 37.1 28.7 19.6 25.7
Benchmark returns # 7.5 14.5 22.3 36.8 31.8 24.0 26.6
Difference of Fund returns and Benchmark returns -3.3 -2.7 -2.1 7.4 -2.7 -4.4 2.2
# Benchmark Index: S&P BSE HEALTHCARE

Investment Info

Investment Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Scheme details

Fund Type Open-Ended
Investment Plan Growth
Launch date May 26, 2004
Benchmark S&P BSE HEALTHCARE
Asset Size (Rs cr) 773.24 (Jun-30-2014)
Minimum Investment Rs.5000
Last Dividend N.A. View Dividend History
Bonus N.A.
Fund Manager Sailesh Rajbhan
View performance of schemes managed by the Fund Manager
Notes N.A

Load Details

Entry Load N.A
Exit Load 1.00%
Load Comments Exit load - 1% if redeemed/switched out on or before completion of 1 yrs from the date of allotment.

Contact Details

Regd. Office One India Bulls Centre - Tower One, 11th & 12th floor, Jupiter Mills Compound, Elphinstone Road, Mumbai , 400013
Tel. No. 022-30994600
Fax No. 91 22 30414899
Email customer_care@reliancemutual.com
Website http://www.reliancemutual.com/

Peer Comparison

Sector - Pharma & Healthcare Crisil Rank Assets (Rs.cr)
3mth (%) 6mth (%) 1yr (%) 3yr (%) 5yr (%)
Reliance Pharma Fund (G) Not Ranked
773.24 11.8 20.2 44.2 19.6 28.8
SBI Pharma Fund (G) Not Ranked
194.91 17.0 25.3 45.7 27.3 28.4
UTI Pharma & Health (G) Not Ranked
149.44 14.0 21.0 37.1 19.6 25.7
Reliance Pharma Fund - Direct (G) Not Ranked
36.13 12.0 20.6 45.2 -- --
SBI Pharma Fund - Direct (G) Not Ranked
21.33 17.2 25.8 46.9 -- --
* Returns over 1 year are Annualised More »

Portfolio

Top Holdings (Jun 30, 14)

Equity Sector Value
(Rs cr)
Asset %
Divis Labs Pharmaceuticals 84.67 10.95
Abbott India Pharmaceuticals 83.66 10.82
Sanofi India Pharmaceuticals 82.20 10.63
Cadila Health Pharmaceuticals 80.65 10.43
Lupin Pharmaceuticals 76.09 9.84
Dr Reddys Labs Pharmaceuticals 65.49 8.47
Sun Pharma Pharmaceuticals 62.40 8.07
Cipla Pharmaceuticals 57.99 7.50
Biocon Pharmaceuticals 38.51 4.98
Indoco Remedies Pharmaceuticals 29.38 3.80

Full Portfolio

Sector Allocation (Jun 30, 14)

Sector %

1-Year

HighLow

Pharmaceuticals 99.30 99.63 93.33

View All Sectors

Asset Allocation (%)(Jun 30, 14)

Equity 99.30
Others 0.00
Debt 0.00
Mutual Funds N.A
Money Market 0.14
Cash / Call 0.56

View All

Concentration

Holdings (%)
Top 5 52.67
Top 10 85.49
Sector (%)
Top 3 99.30

News & Videos

Messages & Community

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.